These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 15617842

  • 1. Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma.
    Talvensaari-Mattila A, Turpeenniemi-Hujanen T.
    Cancer Lett; 2005 Jan 20; 217(2):237-42. PubMed ID: 15617842
    [Abstract] [Full Text] [Related]

  • 2. High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma.
    Talvensaari-Mattila A, Turpeenniemi-Hujanen T.
    Breast Cancer Res Treat; 2005 Jan 20; 89(1):29-34. PubMed ID: 15666194
    [Abstract] [Full Text] [Related]

  • 3. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients.
    Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T, Talieri M.
    Br J Cancer; 2001 Jun 01; 84(11):1488-96. PubMed ID: 11384099
    [Abstract] [Full Text] [Related]

  • 4. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S, Pääkkö P, Soini Y, Mäkitaro R, Kinnula V, Turpeenniemi-Hujanen T.
    Cancer Lett; 2006 May 08; 236(1):125-32. PubMed ID: 15982804
    [Abstract] [Full Text] [Related]

  • 5. Matrix metalloproteinase-9 (MMP-9) immunoreactive protein has modest prognostic value in locally advanced breast carcinoma patients treated with an adjuvant antiestrogen therapy.
    Rahko E, Jukkola A, Melkko J, Paavo P, Bloigu R, Talvensaari-Mattila A, Turpeenniemi-Hujanen T.
    Anticancer Res; 2004 May 08; 24(6):4247-53. PubMed ID: 15736480
    [Abstract] [Full Text] [Related]

  • 6. Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer.
    Leppä S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I.
    Breast Cancer Res Treat; 2005 Mar 08; 90(2):117-25. PubMed ID: 15803358
    [Abstract] [Full Text] [Related]

  • 7. Elevated preoperative serum ICTP is a prognostic factor for overall and disease-free survival in breast cancer.
    Keskikuru R, Bloigu R, Risteli J, Kataja V, Jukkola A.
    Oncol Rep; 2002 Mar 08; 9(6):1323-7. PubMed ID: 12375042
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Low serum level of pro-matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma.
    Kuvaja P, Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T.
    Hum Pathol; 2006 Oct 08; 37(10):1316-23. PubMed ID: 16949931
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.
    Wu CY, Wu MS, Chiang EP, Chen YJ, Chen CJ, Chi NH, Shih YT, Chen GH, Lin JT.
    Clin Cancer Res; 2007 Apr 01; 13(7):2054-60. PubMed ID: 17404086
    [Abstract] [Full Text] [Related]

  • 14. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
    Sliwowska I, Kopczyński Z.
    Wiad Lek; 2007 Apr 01; 60(5-6):241-7. PubMed ID: 17966888
    [Abstract] [Full Text] [Related]

  • 15. High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma.
    Cheng S, Tada M, Hida Y, Asano T, Kuramae T, Takemoto N, Hamada J, Miyamoto M, Hirano S, Kondo S, Moriuchi T.
    J Surg Res; 2008 May 01; 146(1):104-9. PubMed ID: 17663001
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
    Di Saverio S, Catena F, Santini D, Ansaloni L, Fogacci T, Mignani S, Leone A, Gazzotti F, Gagliardi S, De Cataldis A, Taffurelli M.
    Breast Cancer Res Treat; 2008 Jun 01; 109(3):405-16. PubMed ID: 17687650
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer.
    Quaranta M, Daniele A, Coviello M, Venneri MT, Abbate I, Caringella ME, Di Tardo S, Divella R, Trerotoli P, Di Gennaro M, Schittulli F, Fransvea E, Giannelli G.
    Anticancer Res; 2007 Jun 01; 27(5B):3593-600. PubMed ID: 17972522
    [Abstract] [Full Text] [Related]

  • 20. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.
    Unsal D, Akyurek N, Uner A, Erpolat OP, Han U, Akmansu M, Mentes BB, Dursun A.
    Am J Clin Oncol; 2008 Feb 01; 31(1):55-63. PubMed ID: 18376229
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.